Skip to main content
Premium Trial:

Request an Annual Quote

CancerGuide, Duke Ink PGx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CancerGuide Diagnostics has signed a research collaboration and license agreement with Duke University focused on the development and commercialization of biomarkers for pharmacogenomic applications, the company said today.

The multi-year agreement gives CancerGuide, which is based near Duke in Durham, NC, exclusive commercial rights to a portfolio of validated molecular signatures that predict patient response to certain therapeutics, as well as access to new molecular discoveries made at the private university.

CancerGuide will use these technologies with its pharmaceutical partners in the drug development process and to develop and market diagnostics through an existing agreement it has with LabCorp.

"CancerGuide has begun a well-characterized genomic knowledge database compiled from years of clinical studies," Geoffrey Ginsburg, director of the Center for Genomic Medicine in the Duke Institute for Genome Sciences and Policy, said in a statement. Ginsburg added that the database "will give drug developers the highest level of actionable data and precision to enhance the likelihood of clinical success of their targeted therapeutics."

Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.